Physician profile
John Benjamin Wilkinson
NPI 1568621803
$770.11
in general payments reported to CMS, 2019-2025
12 companies · $20.25 in 2025
The $20.25 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2020: $50.34 · 2021: $52.81 · 2022: $26.46 · 2023: $332 · 2024: $156 · 2025: $20.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $507.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $351.64 | 2023-2025 | Prolaris |
| Viewray Technologies INC | $159.35 | 2019-2022 | |
| Siemens Medical Solutions USA, INC. | $69.11 | 2024 | Varian Ethos Treatment Planning |
| West Therapeutics Development, LLC | $39.47 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $32.89 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.49 | 2023 | Alunbrig |
| Monteris Medical Corporation | $16.53 | 2024 | Neuroblate |
| Eisai INC. | $16.30 | 2024 | |
| Glaxosmithkline, LLC. | $15.78 | 2020 | |
| Novocure INC. | $15.01 | 2020 | |
| Emd Serono, INC. | $14.78 | 2023 | Bavencio |
| Pfizer INC. | $13.76 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wilkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.